| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/12/2009 | US20090069347 2-phenoxy pyrimidinone analogues |
| 03/12/2009 | US20090069340 Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders |
| 03/12/2009 | US20090069338 Method for predicting skin sensitizing activity of compounds |
| 03/12/2009 | US20090069337 3' substituted compounds having 5-ht6 receptor affinity |
| 03/12/2009 | US20090069325 Piperidine Derivatives Useful as Modulators of Chemokine Receptor Activity |
| 03/12/2009 | US20090069320 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof |
| 03/12/2009 | US20090069319 Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| 03/12/2009 | US20090069313 Novel MAO-A inhibitors |
| 03/12/2009 | US20090069303 Phthalazinone derivatives |
| 03/12/2009 | US20090069301 Acridine and Quinoline Derivatives as Sirtuin Modulators |
| 03/12/2009 | US20090069298 Pyrazolo[1,5-A]Pyrimidine Compounds |
| 03/12/2009 | US20090069293 Succinoylamino benzodiazepines as inhibitors of ab protein production |
| 03/12/2009 | US20090069292 Liquid Formulations |
| 03/12/2009 | US20090069285 Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitor Activity |
| 03/12/2009 | US20090069284 Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| 03/12/2009 | US20090069267 Central administration of stable formulations of therapeutic agents for cns conditions |
| 03/12/2009 | US20090069261 Gene therapy for spinal cord disorders |
| 03/12/2009 | US20090069258 Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
| 03/12/2009 | US20090069257 Method of achieving persistent Transgene expression |
| 03/12/2009 | US20090069251 Use Of Urokinase Inhibitors for the Treatment and/or Prevention of Neuropathological Diseases |
| 03/12/2009 | US20090069241 Compositions and Methods for Use of Pigment Epithelial Derived Factor (PEDF) Peptide Fragments |
| 03/12/2009 | US20090069238 Activatable clostridial toxins |
| 03/12/2009 | US20090069237 Methods and compositions for treating conditions |
| 03/12/2009 | US20090069234 Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| 03/12/2009 | US20090069230 Gdnf-derived peptides |
| 03/12/2009 | US20090068289 Formulation for menopausal women |
| 03/12/2009 | US20090068273 Prophylaxis of respiratory disorders such as asthma; composition with PDE4 inhibitor, corticosteroid hibitor or anticholinergic agent; 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol or salt |
| 03/12/2009 | US20090068206 Delivery of pharmaceutical agents via the human insulin receptor |
| 03/12/2009 | US20090068155 Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system |
| 03/12/2009 | US20090068152 Gene transfer for regulating smooth muscle tone |
| 03/12/2009 | US20090068143 Orally effective cannabinoid analogs |
| 03/12/2009 | US20090068139 LOOP PEPTIDE AND TGF alpha FOR STIMULATING STEM CELL PROLIFERATION AND MIGRATION |
| 03/12/2009 | US20090068101 A1 Adenosine Receptor Antagonists |
| 03/12/2009 | CA2703831A1 Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| 03/12/2009 | CA2699172A1 Compositions and methods for delivery of poorly soluble drugs |
| 03/12/2009 | CA2698838A1 Novel phenylurea derivatives, inhibitors of the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 03/12/2009 | CA2698780A1 Use of glp-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission |
| 03/12/2009 | CA2698766A1 Use of gip for the treatment of disorders associated with dysfunctional synaptic transmission |
| 03/12/2009 | CA2698665A1 Pharmaceutical composition for inhibiting amyloid-beta protein accumulation |
| 03/12/2009 | CA2698396A1 Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof |
| 03/12/2009 | CA2697941A1 Piperazine derivative having affinity for the histamine h3 receptor |
| 03/11/2009 | EP2034014A1 Therapeutic agent for alzheimer's disease |
| 03/11/2009 | EP2034009A2 Compositions and methods for restoring immune responsiveness in patients with immunological defects basing on cd3/cd28 costimulation |
| 03/11/2009 | EP2033972A1 Screening method for candidate drugs |
| 03/11/2009 | EP2033963A1 Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives |
| 03/11/2009 | EP2033953A1 Vanilloid receptor modulators |
| 03/11/2009 | EP2033951A2 2-Piperazine-pyridines useful for treating pain |
| 03/11/2009 | EP2033653A1 A chinese medicine composition and preparation method and use thereof |
| 03/11/2009 | EP2033647A1 Agent against psychosocial stresses |
| 03/11/2009 | EP2033644A1 Spiroindene and spiroindane compounds |
| 03/11/2009 | EP2033634A1 Agent for increasing testosterone level |
| 03/11/2009 | EP2032987A2 Pharmacological treatment of cognitive impairment |
| 03/11/2009 | EP2032596A1 Neuroprotective compounds and uses thereof |
| 03/11/2009 | EP2032594A1 Glycyrrhetinic acid derivatives |
| 03/11/2009 | EP2032584A2 Thiadiazole compounds and methods of use thereof |
| 03/11/2009 | EP2032575A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use |
| 03/11/2009 | EP2032574A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use |
| 03/11/2009 | EP2032568A2 Polycyclic heterocyclic compounds and their use as modulators of the metabotropic glutamate 5 receptor |
| 03/11/2009 | EP2032558A1 Benzazepine derivatives as monoamine reuptake inhibitors |
| 03/11/2009 | EP2032542A2 Heterocyclic aspartyl protease inhibitors |
| 03/11/2009 | EP2032536A2 Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| 03/11/2009 | EP2032534A1 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
| 03/11/2009 | EP2032142A2 Novel compounds |
| 03/11/2009 | EP2032138A2 Aminothiazole derivatives as inhibitors of mark |
| 03/11/2009 | EP2032136A1 Compositions and kits comprising a melatonin component and a chondroprotective component |
| 03/11/2009 | EP2032135A2 Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist |
| 03/11/2009 | EP2032133A2 Compositions and kits comprising a melatonin component and an omega-3-fatty acid component |
| 03/11/2009 | EP2031965A2 Novel compounds |
| 03/11/2009 | EP1863767B1 Metabolites for nk-i antagonists for emesis |
| 03/11/2009 | EP1667770B1 Method for the production of derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro [3a,3,2][ 2]- benzazepine |
| 03/11/2009 | EP1524981B1 Sustained release formulations comprising lamotrigine |
| 03/11/2009 | EP1485364B1 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| 03/11/2009 | EP1411899B1 Taste masking composition |
| 03/11/2009 | EP1358165B1 Imidazole derivatives |
| 03/11/2009 | EP1349840B1 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 03/11/2009 | EP1319659B1 Triazinones and medicinal use thereof |
| 03/11/2009 | CN101384601A Novel 6-amino-morphinan derivatives, method of manufacturing them and their application as analgesics |
| 03/11/2009 | CN101384594A Condensed heterocyclic compounds useful as dpp-iv inhibitors |
| 03/11/2009 | CN101384588A Process for preparing intermediates to 5-ht4 receptor agonist compounds |
| 03/11/2009 | CN101384581A Benzoyl-piperidine derivatives as 5HT2/D3 modulators |
| 03/11/2009 | CN101384578A Radioligands for the 5 -ht1b receptor |
| 03/11/2009 | CN101384557A Substituted imidazoline derivatives |
| 03/11/2009 | CN101384279A Anti-amyloid immunogenic compositions, methods and uses |
| 03/11/2009 | CN101384267A Ibandronate regimen for treating metastatic bone pain |
| 03/11/2009 | CN101384263A Triazole compounds suitable for treating disorders that respond to modulaiont of the dopamine d3 receptor |
| 03/11/2009 | CN101381725A Circular dumbbell decoy oligodeoxynucleotide (CDODN) containing transcription DNA binding sites |
| 03/11/2009 | CN101381409A N-terminally chemically modified protein compositions and methods |
| 03/11/2009 | CN101381408A Cobratide extraction method, cobratide extracted thereby and formulation containing cobratide |
| 03/11/2009 | CN101381403A Alpha type conotoxin peptide derivates and use thereof |
| 03/11/2009 | CN101381366A Benzimidazole derivative and its use as a ii receptor antagonist |
| 03/11/2009 | CN101380464A Method for treating a movement disorder |
| 03/11/2009 | CN101380433A Combination with antialcoholism action and preparation method thereof |
| 03/11/2009 | CN101380420A Mental-refreshing and brain-awaking injection and production technique thereof |
| 03/11/2009 | CN101380401A Traditional Chinese medicament for treating hemiplegia and cerebral palsy |
| 03/11/2009 | CN101380399A Medicine composition of protracted withdrawal syndrome after heroin-addicts detoxify |
| 03/11/2009 | CN101380397A Hongjing tranquilization paste |
| 03/11/2009 | CN101380388A Traditional Chinese medicine preparation for treating vascular headache and preparation method and use thereof |
| 03/11/2009 | CN101380383A Traditional Chinese medicine combination for treating mental diseases |
| 03/11/2009 | CN101380378A Medicine composition for preventing the birth defect and improving the memory |
| 03/11/2009 | CN101380377A Medicine composition for preventing the birth defect and improving the memory |